Nguyen Anh T N, Baltos Jo-Anne, Thomas Trayder, Nguyen Toan D, Muñoz Laura López, Gregory Karen J, White Paul J, Sexton Patrick M, Christopoulos Arthur, May Lauren T
Monash Institute of Pharmaceutical Sciences (A.T.N.N., J.-A.B., T.T., L.L.M, K.J.G, P.J.W, P.M.S, A.C., L.T.M), Monash e-Research Centre (T.D.N), and Department of Pharmacology (A.T.N.N, J.-A.B., K.J.G., P.M.S., A.C., L.T.M), Monash University, Parkville, Victoria, Australia.
Monash Institute of Pharmaceutical Sciences (A.T.N.N., J.-A.B., T.T., L.L.M, K.J.G, P.J.W, P.M.S, A.C., L.T.M), Monash e-Research Centre (T.D.N), and Department of Pharmacology (A.T.N.N, J.-A.B., K.J.G., P.M.S., A.C., L.T.M), Monash University, Parkville, Victoria, Australia
Mol Pharmacol. 2016 Dec;90(6):703-714. doi: 10.1124/mol.116.105007. Epub 2016 Sep 28.
The adenosine A G protein-coupled receptor (AAR) is an important therapeutic target implicated in a wide range of cardiovascular and neuronal disorders. Although it is well established that the AAR orthosteric site is located within the receptor's transmembrane (TM) bundle, prior studies have implicated extracellular loop 2 (ECL2) as having a significant role in contributing to orthosteric ligand affinity and signaling for various G protein-coupled receptors (GPCRs). We thus performed extensive alanine scanning mutagenesis of AAR-ECL2 to explore the role of this domain on AAR orthosteric ligand pharmacology. Using quantitative analytical approaches and molecular modeling, we identified ECL2 residues that interact either directly or indirectly with orthosteric agonists and antagonists. Discrete mutations proximal to a conserved ECL2-TM3 disulfide bond selectively affected orthosteric ligand affinity, whereas a cluster of five residues near the TM4-ECL2 juncture influenced orthosteric agonist efficacy. A combination of ligand docking, molecular dynamics simulations, and mutagenesis results suggested that the orthosteric agonist 5'-N-ethylcarboxamidoadenosine binds transiently to an extracellular vestibule formed by ECL2 and the top of TM5 and TM7, prior to entry into the canonical TM bundle orthosteric site. Collectively, this study highlights a key role for ECL2 in AAR orthosteric ligand binding and receptor activation.
腺苷A G蛋白偶联受体(AAR)是一个重要的治疗靶点,涉及多种心血管和神经疾病。尽管已经明确AAR的正构位点位于受体的跨膜(TM)束内,但先前的研究表明,细胞外环2(ECL2)在多种G蛋白偶联受体(GPCR)的正构配体亲和力和信号传导中起着重要作用。因此,我们对AAR-ECL2进行了广泛的丙氨酸扫描诱变,以探索该结构域在AAR正构配体药理学中的作用。通过定量分析方法和分子建模,我们确定了与正构激动剂和拮抗剂直接或间接相互作用的ECL2残基。靠近保守的ECL2-TM3二硫键的离散突变选择性地影响正构配体亲和力,而TM4-ECL2交界处附近的五个残基簇影响正构激动剂的效力。配体对接、分子动力学模拟和诱变结果的结合表明,正构激动剂5'-N-乙基羧酰胺腺苷在进入经典的TM束正构位点之前,会短暂地结合到由ECL2以及TM5和TM7顶部形成的细胞外前庭。总的来说,这项研究突出了ECL2在AAR正构配体结合和受体激活中的关键作用。